Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acoramidis - BridgeBio Pharma

Next Previous
Drug Profile

Acoramidis - BridgeBio Pharma

Alternative Names: Acoramidis hydrochloride; AG-10; AG10 hydrochloride; ALXN 2060; Attruby; BBP-265; BEYONTTRA; Beyonttra

Latest Information Update: 04 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer Alexion AstraZeneca Rare Disease; BridgeBio Pharma; Eidos Therapeutics
  • Class Benzoic acids; Ethers; Fluorobenzenes; Pyrazoles; Small molecules
  • Mechanism of Action Prealbumin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Transthyretin-related hereditary amyloidosis

Most Recent Events

  • 30 Aug 2025 Efficacy data from the phase-III ATTRibute-CM trial in Transthyretin-related hereditary amyloidosis released by BridgeBio Pharma
  • 25 Aug 2025 Adverse events data from a phase III ATTRibute-CM trial for Transthyretin amyloidosis cardiomyopathy released by BridgeBio Pharma
  • 11 Aug 2025 Eidos Therapeutics plans a phase III trial for Familial amyloid neuropathy and Transthyretin related hereditary amyloidosis (Treatment experienced ) (PO) in November 2025 (NCT07116473)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top